InspireMD Announces Publication of an Independent Imaging Study Highlighting the Advantages of CGuard EPS Compared to Another Next Generation Carotid Stent
January 19, 2018 10:18 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Jan. 19, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD’s CGuard EPS Demonstrates Improved Outcomes over Carotid Endarterectomy in 50 Patient Comparative Study; Preliminary Results Featured at the 7th Munich Vascular Conference 2017
December 07, 2017 12:23 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Dec. 07, 2017 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular...
InspireMD Announces Preliminary 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard™ EPS
December 05, 2017 13:00 ET
|
InspireMD, Inc.
TEL AVIV, ISRAEL, Dec. 05, 2017 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD Announces Expansion of its Distribution Network for CGuard™ EPS in Australia, New Zealand and Vietnam
December 04, 2017 09:45 ET
|
InspireMD, Inc.
TEL AVIV, lSRAEL, Dec. 04, 2017 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...